Cargando…
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057421/ https://www.ncbi.nlm.nih.gov/pubmed/32098830 http://dx.doi.org/10.1136/jitc-2019-000461 |
_version_ | 1783503653807587328 |
---|---|
author | Hotta, Katsuyuki Fujimoto, Nobukazu |
author_facet | Hotta, Katsuyuki Fujimoto, Nobukazu |
author_sort | Hotta, Katsuyuki |
collection | PubMed |
description | Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both first-line and salvage therapies. Specifically, in the Japanese single-arm, phase II trial, the MERIT trial, nivolumab, an antiprogrammed cell death 1 (PD-1) antibody showed favorable efficacy when used as a salvage therapy. Currently, multiple ICI monotherapy or combination therapy trials have been conducted, which could provide further evidence. Among available ICIs, the anti-PD-1 antibody is promising for unresectable MPM, despite the limited efficacy of anti-CTLA4 monotherapy. Ongoing studies will further confirm the potential efficacy of ICIs for MPM, as observed across other malignancies. It is also crucial to identify any clinically useful predictive biomarkers that could reveal ICIs with maximal effects in MPM. |
format | Online Article Text |
id | pubmed-7057421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-70574212020-03-05 Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma Hotta, Katsuyuki Fujimoto, Nobukazu J Immunother Cancer Review Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both first-line and salvage therapies. Specifically, in the Japanese single-arm, phase II trial, the MERIT trial, nivolumab, an antiprogrammed cell death 1 (PD-1) antibody showed favorable efficacy when used as a salvage therapy. Currently, multiple ICI monotherapy or combination therapy trials have been conducted, which could provide further evidence. Among available ICIs, the anti-PD-1 antibody is promising for unresectable MPM, despite the limited efficacy of anti-CTLA4 monotherapy. Ongoing studies will further confirm the potential efficacy of ICIs for MPM, as observed across other malignancies. It is also crucial to identify any clinically useful predictive biomarkers that could reveal ICIs with maximal effects in MPM. BMJ Publishing Group 2020-02-24 /pmc/articles/PMC7057421/ /pubmed/32098830 http://dx.doi.org/10.1136/jitc-2019-000461 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Review Hotta, Katsuyuki Fujimoto, Nobukazu Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma |
title | Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma |
title_full | Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma |
title_fullStr | Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma |
title_full_unstemmed | Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma |
title_short | Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma |
title_sort | current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057421/ https://www.ncbi.nlm.nih.gov/pubmed/32098830 http://dx.doi.org/10.1136/jitc-2019-000461 |
work_keys_str_mv | AT hottakatsuyuki currentevidenceandfutureperspectivesofimmunecheckpointinhibitorsinunresectablemalignantpleuralmesothelioma AT fujimotonobukazu currentevidenceandfutureperspectivesofimmunecheckpointinhibitorsinunresectablemalignantpleuralmesothelioma |